BNTC · Benitec Biopharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q2 '24 | Q1 '25 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | - | $0 | $0 | $0 | $0 | $0 | $14.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.30M | $5.83M | $3.37M | - | $5.98M | $5.07M | $3.58M | $2.57M | $4.43M | $3.76M |
| SG&A | $7.28M | $7.54M | $6.43M | - | $4.21M | $3.54M | $2.21M | $1.58M | $1.55M | $1.86M |
| Total Operating Expenses | $13.58M | $13.38M | $9.80M | - | $10.19M | $8.61M | $5.79M | $4.14M | $5.87M | $5.62M |
| D&A | $14.0K | $14.0K | $13.0K | - | $13.0K | $14.0K | $25.0K | $25.0K | $19.0K | $41.0K |
| Operating Income | ($13.58M) | ($13.38M) | ($9.80M) | - | ($10.19M) | ($8.61M) | ($5.79M) | ($4.14M) | ($5.87M) | ($5.61M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($11.94M) | ($11.84M) | ($8.96M) | - | ($9.35M) | ($7.36M) | ($5.06M) | ($4.28M) | ($5.95M) | ($5.41M) |
| EPS - Basic | ($0.24) | ($0.26) | ($0.22) | - | ($0.24) | ($0.33) | ($0.48) | ($1.64) | ($2.76) | ($3.40) |
| EPS - Diluted | ($0.24) | ($0.26) | ($0.22) | - | ($0.24) | ($0.33) | ($0.48) | ($1.64) | ($2.76) | ($10.03) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q2 '24 | Q1 '25 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $184.76M | $188.79M | $94.48M | $97.74M | $103.58M | $78.28M | $67.84M | $14.10M | $25.86M | $2.48M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $635.0K | $1.02M | $271.0K | $201.0K | $433.0K | $593.0K | $903.0K | $815.0K | $1.53M | $1.14M |
| Current Assets | $186.02M | $189.59M | $95.08M | $98.52M | $104.01M | $78.71M | $68.33M | $14.37M | $26.41M | $3.73M |
| Total Assets | $187.00M | $190.68M | $96.03M | $99.59M | $105.21M | $79.07M | $68.77M | $15.00M | $27.05M | $4.46M |
| Current Liabilities | $3.27M | $2.80M | $2.02M | $1.80M | $7.03M | $3.09M | $4.55M | $3.44M | $4.53M | $3.98M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.67M | $3.32M | $2.43M | $2.30M | $7.64M | $3.13M | $4.59M | $3.50M | $4.75M | $4.26M |
| Stockholders' Equity | $183.33M | $187.36M | $93.60M | $97.30M | $97.57M | $75.94M | $64.18M | $11.50M | $22.31M | $202.0K |
| Retained Earnings | ($260.91M) | ($248.98M) | ($237.14M) | ($228.18M) | ($212.03M) | ($202.68M) | ($195.32M) | ($184.92M) | ($173.84M) | ($167.89M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q2 '24 | Q1 '25 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.35M) | - | - | - | ($4.59M) | - | ($4.58M) | - |
| Investing Cash Flow | - | - | $0 | - | - | - | $0 | - | $0 | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $21.66M | - | $27.92M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q2 '24 | Q1 '25 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | -40071.4% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | -39778.6% |
| Net margin | - | - | - | - | - | - | - | - | - | -38650.0% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | 26864.3% |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | 13307.1% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.4% | -6.2% | -9.3% | - | -8.9% | -9.3% | -7.4% | -28.5% | -22.0% | -121.2% |
| Return on equity | -6.5% | -6.3% | -9.6% | - | -9.6% | -9.7% | -7.9% | -37.2% | -26.7% | -2678.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 56.82 | 67.69 | 46.95 | 54.67 | 14.80 | 25.48 | 15.01 | 4.18 | 5.83 | 0.94 |
| Quick ratio | 56.82 | 67.69 | 46.95 | 54.67 | 14.80 | 25.48 | 15.01 | 4.18 | 5.83 | 0.94 |
| Cash ratio | 56.43 | 67.40 | 46.66 | 54.24 | 14.74 | 25.34 | 14.90 | 4.10 | 5.70 | 0.62 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.02 | 1.02 | 1.03 | 1.02 | 1.08 | 1.04 | 1.07 | 1.30 | 1.21 | 22.10 |
| Liabilities / Assets | 0.02 | 0.02 | 0.03 | 0.02 | 0.07 | 0.04 | 0.07 | 0.23 | 0.18 | 0.95 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.9x | 3.3x | 6.2x | - | 5.1x | 3.7x | 1.5x | 1.2x | 0.3x | 554.4x |
| P / S | - | - | - | - | - | - | - | - | - | 7998.8x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | -100.0% | - | -100.0% | - | -44.0% |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -33.3% | - | -69.3% | - | -146.0% | -53.5% | 1.4% | 4.6% | -28.3% | -16.0% |
| Net income growth (YoY) | -27.6% | - | -77.2% | - | -118.6% | -36.0% | 15.0% | 2.7% | -16.9% | -12.2% |
| EPS growth (YoY) | 0.0% | - | 54.2% | - | 85.4% | 96.7% | 82.6% | -925.0% | -345.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 87.9% | 92.6% | 45.8% | 28.1% | 748.4% | 37494.6% | 187.7% | 144.0% | 52.7% | -93.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Benitec Biopharma Inc. against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Jun 1, 2018 | $0.7650 |